Background
Titles
- Assistant Professor of Urology
- Assistant Professor of Oncology
Sarah R. Amend, Ph.D.
Leduc MS, Lyons M, Darvishi K, Walsh K, Sheehan S, Amend S, Cox A, Orho-Melander M, Kathiresan S, Paigen B, Korstanje R. The mouse QTL map helps interpret human genome-wide association studies for HDL cholesterol. J Lipid Res. 2011 Jun;52(6):1139-49.
Amend SR, Uluckan O, Hurchla M, Leib D, Novack DV, Silva M, Frazier W, Weilbaecher KN. Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts. J Bone Miner Res. 2015 Jan;30(1):106-15.
Amend SR, Wilson WC, Chu L, Lu L, Liu P, Serie D, Su X, Xu Y, Wang D, Gramolini A, Wen XY, O'Neal J, Hurchla M, Vachon CM, Colditz G, Vij R, Weilbaecher KN, Tomasson MH. Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types. PLoS One. 2015 May 28;10(5):e0127828.
Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE,Pluard T, Ademuyiwa FO, Romagnoli B, Tuffin G, Chevalier E, Luker GD, Bauer M, Zimmermann J, Aft RL,Dembowsky K, Weilbaecher KN. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 Nov;14(11):2473- 85.
Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, Fox GC, Kobayashi T, Steri V, Roomp K, Fontana F,Hurchla MA, Knolhoff BL, Meyer MA, Morgan EA, Tomasson JC, Novack JS, Zou W, Faccio R, Novack DV, Robinson SD, Teitelbaum SL, DeNardo DG, Schneider JG, Weilbaecher KN. Antagonizing Integrin β3 Increases Immunosuppression in Cancer. Cancer Res. 2016 Jun 15;76(12):3484-95.
Parsana P, Amend SR, Hernandez J, Pienta KJ, Battle A. Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration. BMC Cancer. 2017 Jun 26;17(1):447.
Axelrod HD, Valkenburg KS, Amend SR, Hicks J, Parsana P, Torga G, De Marzo A, and Pienta KJ. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Molecular Cancer Research. 2019 Feb;17(2):356-369.
Dong L, Zhang Z, Smith K, Kuczler M, Reyes D, Amend SR, Cho YK, Xue W, Pienta KJ. The combination of size-based separation and selection-free technology provides higher circulating tumor cells detection sensitivity than either method alone in patients with metastatic prostate cancer. BJU International. 2020.
Lin KC, Sun Y, Torga G, Sherpa P, Zhao Y, Qu J, Amend SR, Pienta KJ, Sturm JC, Austin RH. An in vitro tumor swamp model of heterogeneous cellular and chemotherapeutic landscapes. Lab on a Chip. In press.
Zieren RC, Dong L, Amend SR, Pienta KJ. Chapter V: Clinical Aspects of Cancer: Classification of Tumors, Their Frequency and Prognosis. Cancer: Prevention, Early Detection, Treatment and Recovery, 167-211. ed. Gary Stein; Wiley Publishers. 2019.
600 N. Wolfe Street
Marburg Building, Room 105A
Baltimore, MD 21287-2101 map